[fr] Différentes approches pharmacologiques systémiques ont été testées pour réduire le risque de resténose et de complications après angioplastie coronaire, avec ou sans stent, objectif prioritaire dans la population diabétique où ce risque est significativement accru. Le but de cet article est de décrire les effets des principales classes médicamenteuses évaluées quant au risque de resténose, à la nécessité de recourir à de nouvelles procédures de revascularisation et à l’incidence des événements cardiaques majeurs (décès, infarctus non mortels et revascularisations). Nous analyserons le rôle des antiagrégants plaquettaires, des acides gras oméga 3, des statines, des anti-inflammatoires, des immunomodulateurs, des anti-oxydants et des inhibiteurs du système rénine-angiotensine. Dans toute la mesure du possible, nous centrerons notre atten tion sur les résultats obtenus dans la population diabétique.
Disciplines :
Cardiovascular & respiratory systems Endocrinology, metabolism & nutrition
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Language :
French
Title :
Prévention de la resténose et des accidents cardiaques après angioplastie coronaire chez le diabétique
Publication date :
2009
Journal title :
Revue Médicale de la Suisse Romande
ISSN :
0035-3655
Publisher :
Société Médicale de la Suisse Romande, Lausanne, Switzerland
** Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary. The Task force on diabetes and cardiovascular diseases of the European society of cardiology (ESC) and of the European association for the study of diabetes (EASD). Eur Heart J 2007;28:88-136.
Berry C, Tardif JC, Bourassa MG. Coronary heart disease in patients with diabetes part II: Recent advances in coronary revascularisation. J Am Coll Cardiol 2007;49:643-656 (Pubitemid 46205040)
Legrand V. Therapy insight: Diabetes and drug-eluting stents. Nature Clin Pract 2007;4:143-150
* Nyssen A, Legrand V, Scheen AJ. Endoprothèses coronaires pharmaco-actives chez les patients diabétiques. Rev Med Suisse 2008;4:1806-1810
Boyden TF, Nallamothu BK, Moscucci M, et al. Meta-analysis of randomized trials of drug-eluting stents versus bare metal stents in patients with diabetes mellitus. Am J Cardiol 2007;99:1399-1402 (Pubitemid 46686640)
Patti G, Nusca A, Di Sciascio G. Meta-analysis comparison (nine trials) of outcomes with drug-eluting stents versus bare metal stents in patients with diabetes mellitus. Am J Cardiol 2008;102:1328-1334
Mahmud E, Bromberg-Marin G, Palakodeti V, et al. Clinical efficacy of drug-eluting stents in diabetic patients: A meta-analysis. J Am Coll Cardiol 2008;51:2385-2395 (Pubitemid 351815166)
Scheen AJ, Warzée F. Diabetes is still a risk factor for restenosis after drug-eluting stent in coronary arteries. Diabetes Care 2004;27:1840-1841 (Pubitemid 38857477)
Paiva MS, Serrano CV, Nicolau JC, et al. Differences in the inflammatory response between patients with and those without diabetes mellitus after coronary stenting. J Interv Cardiol 2008;21:403-409
Piatti P, Di Mario C, Monti LD, et al. Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting Circulation 2003;108:2074-81.
* Nyssen A, Legrand D, De Flines J, Legrand V, Scheen AJ. Effets des médicaments antidiabétiques sur le risque de resténose et sur l'incidence des complications cardiaques après angioplastie coronaire. Sang Thrombose Vaisseaux 2009;21:133-139
Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications: A systematic review. Arch Intern Med 2008;168:2070-2080
* Geng D, Jin D, Wu W, et al. Effect of thiazolidinediones on in-stent restenosis in patients after coronary stenting: A meta-analysis of randomized controlled trials. Atherosclerosis 2009;202:521-528
* Douglas JS. Pharmacologic approaches to restenosis prevention. Am J Cardiol 2007;100(Suppl.):10K-6.
Nyssen A, Legrand V, Scheen AJ. Risque de resténose et d'événements cardiaques après angioplastie coronaire chez le patient diabétique: réduction par des approches pharmacologiques systémiques. Rev Med Liège 2009;64:192-198
Schwartz L, Bourassa MG, Lesperance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous coronary intervention. N Engl J Med 1988;318:1714-1719
Mehta S, Yusuf S, Peters R, et al. Effects of pre-treatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001;358:527-533 (Pubitemid 32772726)
Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002;288:2411-2420
Bonello L, Camoin-Jau L, Armero S, et al. Tailored Clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009;103:5-10.
Lee S, Park S, Kim Y, et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mallitus. The DECLARE-DIABETES trial. J Am Coll Cardiol 2008;51:1181-1187
Ahn Y, Jeong M, Jeong J, et al. Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients. Circ J 2008;72:35-39
Biondi-Zoccai G, Lotrionte M, Anselmino M, et al. Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention. Am Heart J 2008;155:1081-1089
Brar SS, Kim J, Brar SK, et al. Long-term outcomes by Clopidogrel duration and stent type in a diabetic population with de novo corornary artery. J Am Coll Cardiol 2008;51:2220-2227
Byrne R, Schulz S, Mehilli J, et al. Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of drug-eluting stent: The intracoronary stenting and antithrombotic regimen: Safety and efficacy of 6 months dual antiplatelet therapy after drug-eluting stenting (ISAR-SAFE) study. Am Heart J 2009;157:620-624
Ho PM, Fihn SD, Wang L, et al. Clopidogrel and long-term outcomes after stent implantation for acute coronary syndrome. Am Heart J 2007;154:846-851 (Pubitemid 350010928)
Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007;297:159-168 (Pubitemid 46089732)
Mehilli J, Kastrati A, Scühlen H, et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 2004;110:3627-3635 (Pubitemid 40003783)
Lopez-Minguez JR, Nogales JM, Gonzalez R, et al. Abciximab offers greater benefits to insulin-dependent diabetic patients undergoing coronary stent implantation. Cardiovasc Revasc Med 2007;8:175-182 (Pubitemid 47332356)
De Luca L, Sardella G, De Persio G, et al. Impact of abciximab on coronary restenosis in diabetic patients undergoing elective paditaxel-eluting stent implantation. A prospective, randomized, placebo-controlled study. Acute Card Care 2008;10:93-99
Jenkins DJ, Josse AR, Dorian P, et al. Heterogeneity in randomized controlled trials of long chain (fish) omega-3 fatty acids in restenosis, secondary prevention and ventricular arrhythmias. J Am Coll Nutr 2008;27:367-378
Balk EM, Lichtenstein AH, Chung M, et al. Effects of omega-3 fatty acids on coronary restenosis, intimamedia thickness, and exercise tolerance: A systematic review. Atherosclerosis 2006;184:237-246 (Pubitemid 43049706)
Walter DH, Schächinger V, Eisner M, et al. Effect of statin therapy on restenosis after coronary stent implantation. Am J Cardiol 2000;85:962-968 (Pubitemid 30176134)
Kamishirado H, Inoue T, Sakuma M, et al. Effects of statins on restenosis after coronary stent implantation. Angiology 2007;58:55-60. (Pubitemid 46272184)
Petronio AS, Amoroso G, Limbruno U, et al. Simvastatin does not inhibit intimai hyperplasia and restenosis but promotes plaque regression in normocholesterolemic patients undergoing coronary stenting: A randomized study with intravascular ultrasound. Am Heart J 2005;149:520-526 (Pubitemid 40585416)
Nishino M, Hoshida S, Kato H, et al. Preprocedural statin administration can reduce thrombotic reaction after stent implantation. Circ J 2008;72:232-237
Iwata A, Miura S, Shirai K, et al. Lower level of low-density lipoprotein cholesterol by statin prevents progression of coronary restenosis after successful stenting in acute myocardial infarction. Intern Med 2006;45:885-890 (Pubitemid 44323004)
Chan AW, Bhatt DL, Chew DP, et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 2003;107:1750-1756
Serruys PW, de Feyter P, Macaya C. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial. JAMA 2002;287:3215-3221 (Pubitemid 34686102)
Chan AW, Bhatt DL, Chew DP, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002;105:691-696
Schömig A, Mehilli J, Holle H, et al. Statin treatment following coronary artery stenting and one-year survival. J Am Coll Cardiol 2002;40:854-861 (Pubitemid 34994977)
Ferrero V, Ribichini F, Pesarini G, et al. Glucocorticoids in the prevention of restenosis after coronary angioplasty. Therapeutic potential. Drugs 2007;67:1243-55. (Pubitemid 46879092)
Versaci F, Gaspardone A, Tomai F, et al. Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS Study). J Am Coll Cardiol 2002;40:1935-4Z (Pubitemid 35425363)
Koo B, Kim Y, Park K, et al. Effect of celecoxib on restenosis after coronary angioplasty with a Taxux stent (COREA-TAXUS trial): An open-label randomised controlled study. Lancet 2007;370:567-574 (Pubitemid 47260623)
Rodriguez AE, Fernandez-Pereira C. Systemic immunosuppressive therapy with oral sirolimus after bare metal stent implantation: The missing alternative in the prevention of coronary restenosis after percutaneous coronary interventions. Recent Patents Cardiovasc Drug Discov 2008;3:201-208
Tardif JC, Grégoire J, Schwartz L, et al. Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation 2003;107:552-558 (Pubitemid 36176803)
Peters S. Can angiotensin receptor antagonists prevent restenosis after stent placement? Am J Cardiovasc Drugs 2002;2:143-148
Wilensky R. Angiotensin-receptor blockers: Revival of the systemic prevention of restenosis? Cardiovasc Drugs Ther 2003;17:63-73.
Peters S, Götting B, Trümmel M, et al. Valsartan for prevention of restenosis after stenting of type B2/C lesions: The VAL-PREST trial. J Invasive Cardiol 2001;13:93-97 (Pubitemid 33761992)
Peters S, Trümmel M, Meyners W, et al. Valsartan versus ACE inhibition after bare metal stent implantation - results of the VALVACE trial. Int J Cardiol 2005;98:331-335 (Pubitemid 40431183)
Peters S. Comparison of efficacy of low- (80mg/day) and high- (160-320mg/day) dose valsartan in the prevention of in-stent restenosis after implantation of bare-metal stents in type B2/C coronary artery lesions. Am J Cardiovasc Drugs 2008;8:88-90. (Pubitemid 351570858)
Peters S, Koehler B, Steffen H, et al. Late lumen loss and follow-up percent diameter stenosis at different doses of oral valsartan six months after bare-metal stent implantation in type B2/C coronary lesions. Int J Cardiol 2009; epub ahead of print.
Kiernan TJ, Yan BP, Cruz-Gonzalez I, et al. Pharmacological and cellular therapies to prevent restenosis after percutaneous transluminal angioplasty and stenting. Cardiovasc Hematol Agents Med Chem 2008;6:116-124 (Pubitemid 351935018)
Ray KK, Seshasai SRK, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: A meta-analysis of randomised controlled trials. Lancet 2009;373:1765-1772
* Delcré S, Anselmino M, Moretti C, et al. Clinical and pharmacological management of a high risk diabetic population undergoing percutaneous coronary interventions. Minerva Cardioangiol 2008;53:267-275
